{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T19:21:06Z","timestamp":1794943266997,"version":"4.9.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T00:00:00Z","timestamp":1595808000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s40262-020-00925-8","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T08:02:30Z","timestamp":1595836950000},"page":"191-203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Model-Informed Precision Dosing of Everolimus: External Validation in Adult Renal Transplant Recipients"],"prefix":"10.1007","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3692-0901","authenticated-orcid":false,"given":"Tom C.","family":"Zwart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk Jan A. R.","family":"Moes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J. M.","family":"van der Boog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk-Jan","family":"Guchelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,27]]},"reference":[{"issue":"5","key":"925_CR1","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/nri2546","volume":"9","author":"AW Thomson","year":"2009","unstructured":"Thomson AW, Turnquist HR, Raimondi G. Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol. 2009;9(5):324\u201337.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"925_CR2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ccr.2007.05.008","volume":"12","author":"DA Guertin","year":"2007","unstructured":"Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9\u201322.","journal-title":"Cancer Cell"},{"issue":"1","key":"925_CR3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/TP.0000000000001447","volume":"101","author":"JW de Fijter","year":"2017","unstructured":"de Fijter JW. Cancer and mTOR inhibitors in transplant recipients. Transplantation. 2017;101(1):45\u201355.","journal-title":"Transplantation"},{"key":"925_CR4","unstructured":"Novartis. Afinitor: prescribing information. 2012. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/022334s036lbl.pdf. Accessed 17 June 2019."},{"key":"925_CR5","unstructured":"European Medicines Agency. Afinitor: EPAR: product information. 2019. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/afinitor-epar-product-information_en.pdf. Accessed 17 June 2019."},{"issue":"2","key":"925_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","volume":"38","author":"M Shipkova","year":"2016","unstructured":"Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit. 2016;38(2):143\u201369.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"925_CR7","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","volume":"102","author":"RB Verheijen","year":"2017","unstructured":"Verheijen RB, Yu H, Schellens JHM, Beijnen JH, Steeghs N, Huitema ADR. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017;102(5):765\u201376.","journal-title":"Clin Pharmacol Ther"},{"key":"925_CR8","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.phrs.2017.04.029","volume":"121","author":"M Deppenweiler","year":"2017","unstructured":"Deppenweiler M, Falkowski S, Saint-Marcoux F, Monchaud C, Picard N, Laroche ML, et al. Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol Res. 2017;121:138\u201344.","journal-title":"Pharmacol Res"},{"issue":"3","key":"925_CR9","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ejca.2013.11.022","volume":"50","author":"A Ravaud","year":"2014","unstructured":"Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer. 2014;50(3):486\u201395.","journal-title":"Eur J Cancer"},{"issue":"1","key":"925_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00280-016-3050-6","volume":"78","author":"D de Wit","year":"2016","unstructured":"de Wit D, Schneider TC, Moes DJ, Roozen CF, den Hartigh J, Gelderblom H, et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. Cancer Chemother Pharmacol. 2016;78(1):63\u201371.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"5","key":"925_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/cpt.659","volume":"101","author":"AS Darwich","year":"2017","unstructured":"Darwich AS, Ogungbenro K, Vinks AA, Powell JR, Reny JL, Marsousi N, et al. Why has model-informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future. Clin Pharmacol Ther. 2017;101(5):646\u201356.","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"925_CR12","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1111\/bcp.13591","volume":"84","author":"R Ter Heine","year":"2018","unstructured":"Ter Heine R, van Erp NP, Guchelaar HJ, de Fijter JW, Reinders MEJ, van Herpen CM, et al. A pharmacological rationale for improved everolimus dosing in oncology and transplant patients. Br J Clin Pharmacol. 2018;84(7):1575\u201386.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"925_CR13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00228-015-1963-3","volume":"72","author":"DJ Moes","year":"2016","unstructured":"Moes DJ, van der Bent SA, Swen JJ, van der Straaten T, Inderson A, Olofsen E, et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. Eur J Clin Pharmacol. 2016;72(2):163\u201374.","journal-title":"Eur J Clin Pharmacol"},{"issue":"10","key":"925_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","volume":"44","author":"S Janmahasatian","year":"2005","unstructured":"Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44(10):1051\u201365.","journal-title":"Clin Pharmacokinet"},{"key":"925_CR15","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ejps.2017.05.056","volume":"109S","author":"NHG Holford","year":"2017","unstructured":"Holford NHG, Anderson BJ. Allometric size: the scientific theory and extension to normal fat mass. Eur J Pharm Sci. 2017;109S:S59\u201364.","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"925_CR16","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/bcp.13901","volume":"85","author":"JA Abrantes","year":"2019","unstructured":"Abrantes JA, Jonsson S, Karlsson MO, Nielsen EI. intercessionvariability in model-based dose individualization using therapeutic drug monitoring data. Br J Clin Pharmacol. 2019;85(6):1326\u201336.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"925_CR17","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1067\/mcp.2001.112969","volume":"69","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Kahan BD, Kaplan B, Lorber M, Winkler M, Rouilly M, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69(1):48\u201356.","journal-title":"Clin Pharmacol Ther"},{"key":"925_CR18","unstructured":"US Food and Drug Administration. Center for Drug Evaluation and Research. Afinitor: clinical pharmacology and biopharmaceutics review. 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022334s000_ClinPharmR.pdf. Accessed 17 June 2019."},{"issue":"11","key":"925_CR19","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s40262-016-0414-3","volume":"55","author":"NP van Erp","year":"2016","unstructured":"van Erp NP, van Herpen CM, de Wit D, Willemsen A, Burger DM, Huitema AD, et al. A semi-physiological population model to quantify the effect of hematocrit on everolimus pharmacokinetics and pharmacodynamics in cancer patients. Clin Pharmacokinet. 2016;55(11):1447\u201356.","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"925_CR20","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1016\/j.transproceed.2007.06.032","volume":"39","author":"A Sanchez Fructuoso","year":"2007","unstructured":"Sanchez Fructuoso A, Calvo N, Moreno MA, Giorgi M, Barrientos A. Study of anemia after late introduction of everolimus in the immunosuppressive treatment of renal transplant patients. Transpl Proc. 2007;39(7):2242\u20134.","journal-title":"Transpl Proc."},{"issue":"4","key":"925_CR21","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1046\/j.1523-1755.2003.00850.x","volume":"63","author":"DV Vlahakos","year":"2003","unstructured":"Vlahakos DV, Marathias KP, Agroyannis B, Madias NE. Posttransplant erythrocytosis. Kidney Int. 2003;63(4):1187\u201394.","journal-title":"Kidney Int"},{"issue":"Suppl. 7A","key":"925_CR22","doi-asserted-by":"publisher","first-page":"11s","DOI":"10.1016\/j.amjmed.2003.12.008","volume":"116","author":"K Knight","year":"2004","unstructured":"Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11s\u201326s.","journal-title":"Am J Med"},{"issue":"7","key":"925_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","volume":"51","author":"DJ Moes","year":"2012","unstructured":"Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51(7):467\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"925_CR24","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40262-017-0582-9","volume":"57","author":"RB Verheijen","year":"2018","unstructured":"Verheijen RB, Atrafi F, Schellens JHM, Beijnen JH, Huitema ADR, Mathijssen RHJ, et al. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial. Clin Pharmacokinet. 2018;57(5):637\u201344.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"925_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13(2):143\u201351.","journal-title":"AAPS J"},{"issue":"12","key":"925_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/psp4.12353","volume":"7","author":"RJ Keizer","year":"2018","unstructured":"Keizer RJ, Ter Heine R, Frymoyer A, Lesko LJ, Mangat R, Goswami S. Model-informed precision dosing at the bedside: scientific challenges and opportunities. CPT Pharmacometr Syst Pharmacol. 2018;7(12):785\u20137.","journal-title":"CPT Pharmacometr Syst Pharmacol."},{"issue":"5","key":"925_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1034\/j.1600-6143.2003.00107.x","volume":"3","author":"JM Kovarik","year":"2003","unstructured":"Kovarik JM, Kaplan B, Silva HT, Kahan BD, Dantal J, McMahon L, et al. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6\u00a0months after kidney transplantation. Am J Transpl. 2003;3(5):606\u201313.","journal-title":"Am J Transpl"},{"issue":"4","key":"925_CR28","first-page":"169","volume":"10","author":"K Budde","year":"2005","unstructured":"Budde K, Fritsche L, Waiser J, Glander P, Slowinski T, Neumayer HH. Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients. Eur J Med Res. 2005;10(4):169\u201374.","journal-title":"Eur J Med Res."},{"issue":"4","key":"925_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9(4):503\u201312.","journal-title":"J Pharmacokinet Biopharm"},{"issue":"2","key":"925_CR30","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.transproceed.2018.08.016","volume":"51","author":"R Valero","year":"2019","unstructured":"Valero R, Sanchez-Fructuoso A, Rodrigo E, Belmar L, Cos MA, Perez-Flores I, et al. Variability of the mammalian target of rapamycin inhibitors is correlated with long-term renal graft survival. Transpl Proc. 2019;51(2):341\u20133.","journal-title":"Transpl Proc."},{"issue":"11","key":"925_CR31","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s40262-018-0646-5","volume":"57","author":"I Robertsen","year":"2018","unstructured":"Robertsen I, Debord J, Asberg A, Marquet P, Woillard JB. A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and Bayesian estimators. Clin Pharmacokinet. 2018;57(11):1459\u201369.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"925_CR32","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10928-018-9600-2","volume":"45","author":"FP Combes","year":"2018","unstructured":"Combes FP, Baneyx G, Coello N, Zhu P, Sallas W, Yin H, et al. Population pharmacokinetics-pharmacodynamics of oral everolimus in patients with seizures associated with tuberous sclerosis complex. J Pharmacokinet Pharmacodyn. 2018;45(5):707\u201319.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"925_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1097\/FTD.0000000000000344","volume":"38","author":"A Tanaka","year":"2016","unstructured":"Tanaka A, Yano I, Shinsako K, Sato E, Fukudo M, Masuda S, et al. Population pharmacokinetics of everolimus in relation to clinical outcomes in patients with advanced renal cell carcinoma. Ther Drug Monit. 2016;38(6):663\u20139.","journal-title":"Ther Drug Monit"},{"issue":"24","key":"925_CR34","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1002\/cncr.28965","volume":"120","author":"NF Saba","year":"2014","unstructured":"Saba NF, Hurwitz SJ, Magliocca K, Kim S, Owonikoko TK, Harvey D, et al. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent\/metastatic squamous cell carcinoma of the head and neck. Cancer. 2014;120(24):3940\u201351.","journal-title":"Cancer"},{"issue":"6","key":"925_CR35","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1097\/FTD.0b013e318273c899","volume":"34","author":"F Lemaitre","year":"2012","unstructured":"Lemaitre F, Bezian E, Goldwirt L, Fernandez C, Farinotti R, Varnous S, et al. Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit. 2012;34(6):686\u201394.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"925_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1067\/mcp.2001.118022","volume":"70","author":"JM Kovarik","year":"2001","unstructured":"Kovarik JM, Hsu CH, McMahon L, Berthier S, Rordorf C. Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther. 2001;70(3):247\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"925_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, Asberg A, Haufroid V, Hesselink DA, Langman L, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report. Ther Drug Monit. 2019;41(3):261\u2013307.","journal-title":"Ther Drug Monit"},{"issue":"5","key":"925_CR38","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","volume":"34","author":"NH Holford","year":"2012","unstructured":"Holford NH, Buclin T. Safe and effective variability: a criterion for dose individualization. Ther Drug Monit. 2012;34(5):565\u20138.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"925_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1111\/bcp.12361","volume":"78","author":"E Storset","year":"2014","unstructured":"Storset E, Holford N, Hennig S, Bergmann TK, Bergan S, Bremer S, et al. Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. Br J Clin Pharmacol. 2014;78(3):509\u201323.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"925_CR40","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/bcp.12703","volume":"80","author":"H de Jonge","year":"2015","unstructured":"de Jonge H, Vanhove T, de Loor H, Verbeke K, Kuypers DR. Progressive decline in tacrolimus clearance after renal transplantation is partially explained by decreasing CYP3A4 activity and increasing haematocrit. Br J Clin Pharmacol. 2015;80(3):548\u201359.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"925_CR41","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1016\/j.transproceed.2015.12.096","volume":"48","author":"S Limsrichamrern","year":"2016","unstructured":"Limsrichamrern S, Chanapul C, Mahawithitwong P, Sirivatanauksorn Y, Kositamongkol P, Asavakarn S, et al. Correlation of hematocrit and tacrolimus level in liver transplant recipients. Transpl Proc. 2016;48(4):1176\u20138.","journal-title":"Transpl Proc."},{"issue":"4","key":"925_CR42","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40262-019-00846-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Hunault CC, Huitema ADR, De Lange DW, Van Maarseveen EM. Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation. Clin Pharmacokinet. 2020;59(4):403\u20138.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"925_CR43","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Van Maarseveen EM, Hunault CC, Moreno JM, Van de Graaf EA, Kirkels JH, et al. Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Clin Pharmacokinet. 2020;59(6):771\u201380.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"925_CR44","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/cpt1979263294","volume":"26","author":"LB Sheiner","year":"1979","unstructured":"Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26(3):294\u2013305.","journal-title":"Clin Pharmacol Ther"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00925-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00925-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,26]],"date-time":"2021-07-26T23:30:17Z","timestamp":1627342217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00925-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,27]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00925-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,27]]},"assertion":[{"value":"27 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nielka P. van Erp\u2019s institution has received research grants from Astellas, Novartis, Ipsen, and Janssen-Cilag and consulting fees from Bayer and Sanofi, none of which were related to the content of this article. Ron J. Keizer is a founder, employee and stockholder for InsightRX. Tom C. Zwart, Dirk Jan A.R. Moes, Paul J.M. van der Boog, Johan W. de Fijter, Henk-Jan Guchelaar and Rob ter Heine have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The NONMEM code used to generate and\/or analyse the data described in this study is provided in the ESM.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"No funding was received for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This research study was conducted retrospectively with data obtained for clinical purposes. We consulted with the scientific committee of the Department of Internal Medicine of Leiden University Medical Center, who determined that our study did not need ethical approval\u00a0or informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}